Cell and gene therapy hold tremendous promise for treating a wide array of diseases, including many that were previously considered untreatable. However, the high production costs associated with these advanced treatments pose a significant barrier to their widespread adoption. Automation emerges
The fields of cell and gene therapy have seen remarkable advancements and transformative updates over the past few years. As biotechnology companies strive to innovate and deliver groundbreaking solutions, significant milestones have been achieved, fostering hope and optimism for addressing some of
Celiac disease is an autoimmune disorder affecting nearly 1% of the global population. This condition, driven by a harmful reaction to gluten found in wheat, rye, and barley, has seen a doubling in its prevalence over the past 25 years. The dire consequences include damage to the small intestine,
The complexity of Type 2 Diabetes Mellitus (T2DM) has prompted scientists to look beyond traditional factors like diet and genetics to better understand this chronic condition. Emerging research highlights the crucial role of the gut microbiota in T2DM pathogenesis and management. This article
The European pharmaceutical landscape is undergoing significant regulatory and research-driven changes. Vifor Pharma’s recent clash with the European Commission, coupled with groundbreaking diabetes research, marks a pivotal moment for healthcare stakeholders. This article delves into these major d
Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as nonalcoholic fatty liver disease (NAFLD), is increasingly recognized for its significant health and economic impacts. Characterized by excessive fat accumulation in the liver, MASLD can escalate to more severe
